All terms

    EU In Vitro Diagnostic Regulation

    Regulation (EU) 2017/746 governing in vitro diagnostic medical devices in the EU.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Regulation (EU) 2017/746 (IVDR) sets out the regulatory framework for in vitro diagnostic medical devices placed on the EU market, replacing Directive 98/79/EC (IVDD). It introduces a risk-based classification (Class A, B, C, D) aligned with IMDRF principles and dramatically expands the role of Notified Bodies.
    What the regulation says
    The EU IVDR (Regulation (EU) 2017/746) establishes a comprehensive regulatory framework for in vitro diagnostic medical devices within the European Union, emphasizing a life-cycle approach to device safety and performance. It mandates stricter requirements for conformity assessment, clinical evidence, and post-market surveillance compared to its predecessor, Directive 98/79/EC.

    What this means in practice

    Under IVDD, roughly 8% of IVDs required Notified Body review. Under IVDR, that figure rises to roughly 80%. Regulation (EU) 2022/112 and Regulation (EU) 2024/1860 staggered transition deadlines through 2027-2029 to prevent supply shortages. Key new obligations include a Performance Evaluation Report (Annex XIII), Post-Market Performance Follow-up (PMPF), Summary of Safety and Performance (SSP) for Class C/D, EU Reference Laboratories for Class D, EUDAMED registration, and Person Responsible for Regulatory Compliance (PRRC) per Article 15. In-house (LDT) tests are permitted under Article 5(5) only with strict justification.

    Examples

    • A SARS-CoV-2 PCR assay: Class D (detection of transmissible agent causing life-threatening disease).
    • A HbA1c self-test: Class C (management of a chronic condition).
    • A pregnancy self-test: Class C (self-testing).
    • A clinical chemistry calibrator: Class B.
    Common pitfalls
    • Assuming legacy IVDD CE certificates transfer automatically. They require a Notified Body application and quality system compliance before the applicable Article 110 deadline.
    • Under-scoping the Performance Evaluation - IVDR requires scientific validity, analytical performance, and clinical performance as three distinct evidence streams.
    • Missing the PMPF plan. It is mandatory even for Class B devices and must be reviewed annually (PSUR for C/D).
    • Treating companion diagnostics as generic IVDs. Article 48 requires consultation with EMA or a national medicines authority.

    Frequently asked questions

    IVDR uses Rules 1-7 (Annex VIII) based on intended purpose and risk to individual and public health. Class D is the highest risk (transmissible agents, blood grouping) and requires EU Reference Laboratory batch testing plus common specifications.

    Cross-references

    Uses

    Contains

    Often confused with

    Shared paths + category

    Latest in MedTech

    Primary references

    3 sources
    Link health: 2 verified 1 unchecked· last checked 2026-06-20
    EUR-Lex·2European Commission·1
    1. 1
      Regulation (EU) 2017/746 (IVDR)
      Verified
      EUR-Lexeur-lex.europa.eu
    2. 2
      Regulation (EU) 2024/1860 (transition amendment)
      Unchecked
      EUR-Lexeur-lex.europa.eu
    3. 3
      MDCG Guidance on IVDR
      Verified
      European Commissionhealth.ec.europa.eu

    Inline markers like [1] jump to the matching reference above.